These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 17642683)

  • 1. Evaluation of immunogenicity and safety of Genevac B: a new recombinant hepatitis B vaccine in comparison with Engerix B and Shanvac B in healthy adults.
    Vijayakumar V; Hari R; Parthiban R; Mehta J; Thyagarajan SP
    Indian J Med Microbiol; 2004; 22(1):34-8. PubMed ID: 17642683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India.
    Velu V; Nandakumar S; Shanmugam S; Jadhav SS; Kulkarni PS; Thyagarajan SP
    World J Gastroenterol; 2007 Jun; 13(22):3084-9. PubMed ID: 17589924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
    Velu V; Nandakumar S; Shanmugam S; Shankar EM; Thangavel S; Kulkarni PS; Thyagarajan SP
    Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
    Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
    J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of indigenous recombinant hepatitis B vaccine (Shanvac-B) in comparison with commercially available vaccine.
    Joshi N; Kumar A; Sreenivas DV; Palan S; Nagarjuna Kumar YR
    Indian J Gastroenterol; 2000; 19(2):71-3. PubMed ID: 10812819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study.
    Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH
    Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
    Raz R; Koren R; Bass D
    Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults.
    Kulkarni PS; Raut SK; Patki PS; Phadke MA; Jadhav SS; Kapre SV; Dhorje SP; Godse SR
    Vaccine; 2006 Apr; 24(17):3457-60. PubMed ID: 16530299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India.
    Shivananda ; Somani V; Srikanth BS; Mohan M; Kulkarni PS
    Clin Vaccine Immunol; 2006 Jun; 13(6):661-4. PubMed ID: 16760324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
    Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reactivity and immunogenicity of Engerix B, the recombinant DNA vaccine against hepatitis B].
    Borcić B; Gasparović V; Mihaljevic I; Aleraj B; Margan IG
    Acta Med Iugosl; 1989; 43(4):247-54. PubMed ID: 2534021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical safety and efficacy of first indigenous recombinant hepatitis B vaccine.
    Kumar A; Joshi N; Sreenivas DV; Palan S; Nagarjuna Kumar YR
    J Assoc Physicians India; 1998 Jul; 46(7):620-2. PubMed ID: 12152846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults.
    Crovari P; Crovari PC; Petrilli RC; Icardi GC; Bonanni P
    Postgrad Med J; 1987; 63 Suppl 2():161-4. PubMed ID: 3317356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
    Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine.
    Young MD; Schneider DL; Zuckerman AJ; Du W; Dickson B; Maddrey WC;
    Hepatology; 2001 Aug; 34(2):372-6. PubMed ID: 11481622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults.
    Van Damme P; Leroux-Roels G; Law B; Diaz-Mitoma F; Desombere I; Collard F; Tornieporth N; Van Herck K
    J Med Virol; 2001 Sep; 65(1):6-13. PubMed ID: 11505437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative immunogenicity of different hepatitis B vaccines among certain high risk groups in India.
    Chadha MS; Arankalle VA; Banerjee K
    J Assoc Physicians India; 1992 Sep; 40(9):584-8. PubMed ID: 1308012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine (YDV) on adults].
    Shi J; Li Z; Zheng L
    Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Apr; 22(2):105-7. PubMed ID: 11860855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.
    Evans TG; Schiff M; Graves B; Agosti J; Barritt ML; Garner D; Holley JL
    Clin Nephrol; 2000 Aug; 54(2):138-42. PubMed ID: 10968690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.